Search and analyze individual stocks with comprehensive metrics

Divi's Laboratories Limited

DIVISLABPharmaceuticals & Biotechnology

Fundamental Score

...

Divi's Laboratories Limited Share Price & Market Analysis

Current Market Price (CMP)
6104.50
No change data available
Market Cap
1.59L (Cr)
Industry
Pharmaceuticals & Biotechnology

Profitability Metrics

Average

Return on Equity

15.35%
Excellent

Return on Capital Employed

20.44%
Excellent

Operating Profit Margin (5Y)

34.98%
Average

Dividend Yield

0.50%

Valuation Metrics

Poor

Price to Earnings

68.89x

Market Capitalization

1.59L (Cr)

Industry P/E

33.97x

Growth Metrics

Excellent

YoY Quarterly Profit Growth

26.74%
Poor

YoY Quarterly Sales Growth

13.79%
Good

Sales Growth (5Y)

11.65%
Average

EPS Growth (5Y)

10.41%
Average

Profit Growth (5Y)

10.41%

Financial Health

Excellent

Debt to Equity

0.00x
Excellent

Interest Coverage

610.00x
Excellent

Free Cash Flow (5Y)

4.69K (Cr)

Ownership Structure

Good

Promoter Holding

51.89%
Good

FII Holding

19.74%
Good

DII Holding

18.96%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Large-cap
Established & liquid; typically steadier returns.
51.89%
Promoter Holding
1.59L (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of DIVISLAB across key market metrics for learning purposes.

Positive Indicators

10 factors identified

Strong Return on Equity (15.35%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (20.44%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.

Strong Operating Margins (34.98%)

Observation: Healthy 5-year operating margins indicate pricing power and cost control.

Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.

Robust Profit Growth (26.74%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture. This suggests positive business trajectory.

Debt-Free Balance Sheet (D/E: 0.00)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.

Strong Interest Coverage (610.00x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.

Strong Cash Generation (₹4694.49 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (51.89%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Strong Institutional Confidence (FII+DII: 38.70%)

Observation: Significant professional investor participation indicates quality recognition.

Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

3 factors identified

Premium Valuation Risk (P/E: 68.89x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations. Consider entry timing carefully.

High P/E Ratio

Observation: Stock may be overvalued relative to earnings.

Analysis: P/E above 30 requires strong growth execution to justify current valuations.

Very High P/E Ratio

Observation: Significant overvaluation risk present.

Analysis: Extremely high P/E ratios indicate potential bubble territory and high downside risk.

📊 Educational Market Overview

Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.

Loading Peer Comparison

Finding companies in the Pharmaceuticals sector...

Financial Statements

Comprehensive financial data for Divi's Laboratories Limited

About DIVISLAB

Company Details

Symbol:DIVISLAB
Industry:Pharmaceuticals & Biotechnology
Sector:Pharmaceuticals

Market Information

Market Cap:1.59L (Cr)
P/E Ratio:68.89
Beta:N/A

Performance

52W High:N/A
52W Low:N/A
Dividend Yield:0.50%

DIVISLAB Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)15.35%
Return on Capital Employed20.44%
Operating Profit Margin (5Y)34.98%
Debt to Equity Ratio0.00
Interest Coverage Ratio610.00

Growth & Valuation

Sales Growth (5Y)11.65%
Profit Growth (5Y)10.41%
EPS Growth (5Y)10.41%
YoY Quarterly Profit Growth26.74%
YoY Quarterly Sales Growth13.79%

Frequently Asked Questions

What is the current price of DIVISLAB?

DIVISLAB is currently trading at ₹6104.50 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of DIVISLAB shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.

What is the P/E ratio of DIVISLAB and what does it mean?

DIVISLAB has a P/E ratio of 68.89x compared to the industry average of 33.97x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹69 for every ₹1 of annual earnings. This is higher than the industry average, suggesting either growth premium or potential overvaluation.

How is DIVISLAB performing according to Bull Run's analysis?

DIVISLAB has a Bull Run fundamental score of 65.7/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 15.35%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.

What sector and industry does DIVISLAB belong to?

DIVISLAB operates in the Pharmaceuticals & Biotechnology industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Divi's Laboratories Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.

What is Return on Equity (ROE) and why is it important for DIVISLAB?

DIVISLAB has an ROE of 15.35%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Divi's Laboratories Limited generates profits from shareholders' equity. An ROE of 15% means the company generates ₹15 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.

How is DIVISLAB's debt-to-equity ratio and what does it indicate?

DIVISLAB has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk. This means the company has ₹0 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.

What is DIVISLAB's dividend yield and is it a good dividend stock?

DIVISLAB offers a dividend yield of 0.50%, which means you receive ₹0.50 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.

How has DIVISLAB grown over the past 5 years?

DIVISLAB has achieved 5-year growth rates of: Sales Growth 11.65%, Profit Growth 10.41%, and EPS Growth 10.41%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.

What is the promoter holding in DIVISLAB and why does it matter?

Promoters hold 51.89% of DIVISLAB shares, with 0.00% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.

How does DIVISLAB compare with its industry peers?

DIVISLAB trades at P/E 68.89x vs industry average 33.97x, with ROE of 15.35% and ROCE of 20.44%. The stock trades at a premium to industry average, which may be justified by superior fundamentals. Peer comparison helps identify whether DIVISLAB is outperforming its competitive set in profitability, growth, and valuation metrics.

What is DIVISLAB's market capitalization and what category does it fall into?

DIVISLAB has a market capitalization of ₹158860 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.

What are the key financial ratios to consider for DIVISLAB?

Key ratios for DIVISLAB: ROE 15.35% (Excellent), ROCE 20.44%, P/E 68.89x, Debt-to-Equity 0.00, Interest Coverage 610.00x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.

How volatile is DIVISLAB stock and what is its beta?

DIVISLAB has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.

What is the 52-week high and low for DIVISLAB?

DIVISLAB has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹6104.50, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.

What are the key risks associated with investing in DIVISLAB?

Key risks for DIVISLAB include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.00), and operational challenges. The stock has a Fundamental Score of 65.7/100, indicating moderate risk requiring careful monitoring. Sector-specific risks in Pharmaceuticals & Biotechnology include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.

What is DIVISLAB's operating profit margin and how has it trended?

DIVISLAB has a 5-year average Operating Profit Margin (OPM) of 34.98%, which is excellent and indicates strong pricing power and cost control. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. This strong margin indicates competitive advantages and operational leverage. Compare with industry peers to understand relative performance.

How is DIVISLAB's quarterly performance in terms of sales and profit growth?

DIVISLAB's recent quarterly performance shows YoY Sales Growth of 13.79% and YoY Profit Growth of 26.74%. This shows decent growth momentum in the business. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.

What is the FII and DII holding pattern in DIVISLAB?

DIVISLAB has FII holding of 19.74% and DII holding of 18.96%, totaling 38.70% institutional ownership. This institutional participation level shows the confidence of professional money managers. Significant FII holding suggests global investor confidence and potential for index inclusion. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.